Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia.
Subscribe to see Incyte Corporation’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Incyte Corporation is a biotechnology company headquartered in Wilmington, United States, founded in 2001. It is publicly listed (INCY) with a market capitalisation of $24.8B. Xcout tracks 32 named people at Incyte Corporation, including William Meury (CEO & Director).
As of 16 November 2026. Source: Xcout Intel.
26 more named people on record for Incyte Corporation, with roles, board committees and tenure — see the full roster →
858 institutions reported a position for the quarter ending 30 June 2026, and 1 insider holds at least 0.1% of the shares.
| Holder | % of shares outstanding |
|---|---|
| Baker Bros. Advisors | 15.20% |
| Vanguard | 10.00% |
| BlackRock | 8.90% |
| Dodge & Cox | 5.90% |
| State Street | 4.80% |
| Other institutions | 55.20% |
The full list of 858 institutions, with share counts and what each bought or sold since the previous quarter.
Sign in to see it, or subscribe →
Source: SEC Form 13F filings, period ending 30 June 2026; shares outstanding from the company's 10-Q as of 21 July 2026. 13F covers the US-listed holdings of investment managers with more than $100 million under management and is filed up to 45 days after the quarter ends. A firm that files under several names (Vanguard files as two managers) is one row, with its filers listed under it. Individuals are company insiders (directors, officers and 10% owners) holding at least 0.1% of the shares, from their latest SEC Form 3, 4 or 5 (newest 10 December 2025), counting shares held directly and through trusts and other entities they report, including high-vote class shares (such as Class B); options and restricted stock units are not counted. They are a separate slice from the 13F institutions, so the ring adds up to 100%: what is left is held by smaller insiders, retail investors and anyone else who does not file.
A few of Incyte Corporation's closest competitors — see the full list of competitors and alternatives →
Amgen Inc. is an American multinational biopharmaceutical and biotechnology company headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing, and delivering innovative medicines to address severe diseases.
Inventisbio is a biopharmaceutical company that focuses on the discovery and development of innovative drugs for major diseases such as tumors, autoimmune diseases, and metabolic disorders. Utilizing an independent research and development platform, the company creates proprietary drug pipelines targeting oncology drivers, kinases, and autoimmune pathways to serve patients globally.
AstraZeneca is an innovative biopharmaceutical company that researches, develops, and manufactures modern medicines for patients. It addresses major medical challenges across therapeutic areas such as oncology, cardiovascular and metabolic diseases, respiratory conditions, and immunology.
NiKang Therapeutics, Inc. is a biotechnology research company headquartered in Wilmington, Delaware, focused on discovering and developing innovative small molecule medicines.
Kite Pharma is a biopharmaceutical company that develops and manufactures custom CAR T-cell therapies to treat certain types of blood cancer. The company utilizes patients' own engineered immune cells to target and attack cancer, serving patients diagnosed with conditions such as lymphomas.
InnoCare Pharma Limited, a biopharmaceutical enterprise, specializes in the discovery, development, and commercialization of therapeutic agents for oncological and autoimmune disorders. Its lead product, Orelabrutinib, a BTK inhibitor, addresses a wide range of conditions, including various forms of relapsed and/or refractory (r/r) lymphomas (such as chronic lymphocytic leukemia, mantle cell lymphoma, Waldenstrom's macroglobulinemia, marginal zone lymphoma, specific diffuse large B-cell lymphomas, and central nervous system lymphoma). It also targets systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder, sometimes utilized in combination therapies. The company's robust pipeline features several key candidates: ICP-192, a pan-FGFR inhibitor in Phase I/II clinical trials for solid tumors, notably cholangiocarcinoma and head and neck cancer; ICP-723, a pan-TRK inhibitor undergoing Phase I evaluation for cancers positive for neurotrophic tyrosine receptor kinase fusion; ICP-332, a novel tyrosine kinase 2 inhibitor in Phase I for autoimmune diseases; and ICP-B02, a bispecific antibody developed for lymphoma treatment. Furthermore, InnoCare is advancing ICP-189, ICP-915, and ICP-B03 for solid tumors; ICP-033 for liver cancer, renal cell carcinoma, colorectal cancer, and other solid malignancies; ICP-488 for autoimmune conditions; ICP-B05, an anti-CC chemokine receptor 8 monoclonal antibody targeting various cancers; ICP-248 for hematological indications; and ICP-490 for both hematology and autoimmune disorders. In addition, the firm offers ICP-B04 (Tafasitamab) for the treatment of DLBCL and other hematological conditions. InnoCare Pharma Limited was established in 2015 and maintains its headquarters in Beijing, China.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Incyte Corporation? Suggest a correction · Work at Incyte Corporation? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.